Proton therapy developer Mevion Medical Systems will receive up to $200 million in financing under a new investment agreement and will launch a joint venture in China.
The investment agreement was led by Chinese investors Hopu Investments and YuanMing Capital and included other Chinese investors, as well as current U.S. investors Caxton Alternative Management, ProQuest Investments, Venrock, and CHL Medical Partners, according to the company. Mevion said the funds will be used to support its worldwide expansion.
In a related development, Mevion and the lead Chinese investors are also forming a joint venture in China to produce, sell, and service proton therapy systems for the Chinese market.
